Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

Strong financial position supports clinical focus on advancing drug

candidates for treatment of lysosomal storage disorders

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the first quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.34 per share ($0.28 per share on a non-GAAP basis) for the three months ended March 31, 2008. As of March 31, 2008, cash, cash equivalents, and marketable securities totaled $154.6 million.

"In the first quarter of 2008, we continued to advance our three lead clinical development programs. We also reported data from multiple clinical trials that add to the growing body of evidence demonstrating that treatment with our oral pharmacological chaperone drug candidates has the potential to benefit patients with Fabry, Gaucher and Pompe disease," said John F. Crowley, President and CEO of Amicus Therapeutics. "In the months ahead in 2008, we will be focused on advancing the global regulatory plan for Amigal Phase 3 development, evaluating opportunities for additional clinical studies in Gaucher and Pompe disease, as well as on identifying new therapeutic areas for applying our pharmacological chaperone technology platform."

Program Advancements

Fabry Disease:

Amigal(TM) (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. In March, clinical investiga
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... Kent, WA (PRWEB) August 28, 2014 ... Synder Filtration’s polymeric membranes to its stable of ... of available molecular weight cut-offs and include membrane filters ... a steady increase in customer demand for our membrane ... a greater variety of flat sheet membranes,” explains Sterlitech ...
(Date:8/28/2014)... Florida State University research team has led to a ... white light, and convert photon energy directly to mechanical ... , Biwu Ma, associate professor in the Department of ... Engineering, created the molecule in a lab about a ... creation has many other unique capabilities. , For example, ...
(Date:8/28/2014)... A new market research report detailing ... from Strategic Consulting, Inc., the leading information resource ... Review, Fourth Edition: Global Review of Microbiology Testing ... compares microbiology test volumes, market values and methods ... and forecasts future volumes and market values through ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3
(Date:8/29/2014)... Tibetan plateau -- the largest topographic anomaly above sea ... profound effect on climate and its reflection of continental ... , Katharine Huntington and colleagues employ a cutting-edge geochemical ... fossil snail shells to investigate the uplift history of ... range widely on the timing of surface uplift of ...
(Date:8/28/2014)... to announce the selection of Dr. Fred Baxendale as ... those who have served ESA for at least 20 ... Society that has reached an extraordinary level. Candidates for ... and then voted on by the ESA membership. Dr. ... Entomology 2014, ESA,s Annual Meeting in Portland, Oregon this ...
(Date:8/28/2014)... expansion of marine protected areas is needed to protect ... to investigators from the Wildlife Conservation Society and other ... saving the largest numbers of species, often at the ... ecological functions. , Many vital ecological functions ... also are food for millions of people. This ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... , The Woods Hole Research Center has released the ... associated carbon stock for the forests and woodlands of ... as the National Biomass and Carbon Dataset (NBCD), produced ... spatial resolution of 30 m. The digital raster ...
... Earth may be able to recover from rising carbon dioxide ... prehistoric event analyzed by a Purdue University-led team. When ... temperatures 56 million years ago, the Earth increased its ability ... recovery that was quicker than anticipated by many models of ...
... arid Namib Desert on the west coast of Africa, one type ... morning fog rolls in, the Stenocara gracilipes species, also known as ... lets the moisture roll down into its mouth, allowing it to ... has developed, Shreerang Chhatre wants to refine, to help the world,s ...
Cached Biology News:WHRC debuts detailed maps of forest canopy height and carbon stock for the conterminous US 2WHRC debuts detailed maps of forest canopy height and carbon stock for the conterminous US 3WHRC debuts detailed maps of forest canopy height and carbon stock for the conterminous US 4Purdue-led team studies Earth's recovery from prehistoric global warming 2Purdue-led team studies Earth's recovery from prehistoric global warming 3MIT: Development in fog harvesting process 2MIT: Development in fog harvesting process 3MIT: Development in fog harvesting process 4
... stainless-steel shaker flask clips, purpose-designed to firmly ... All clips are equipped with a top ... include a bottom retainer spring, and silicon ... expensive glassware. Clips include the required ...
... immuncapture enzyme-activity assay based on measurenment of ... monoclonal antibody coated microtiter plate. The procedure ... samples or controls, 2nd enzyme reaction) ... is intended for the determination of human ...
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. The ... as a one-cabinet model, allowing ...
... Source: Pseudomonas atlantica Description: Beta-Agarase ... RNA fragments from low-melting-temperature agarose. Beta-Agarase ... disaccharides. Tested User Friendly Properties: Heat ... 30,000 Da Optimum pH: 6.5 Purity: ...
Biology Products: